BACKGROUND Demographic changes impose a number of issues regarding the biological treatment of elderly patients with moderate-to-severe psoriasis. PATIENTS AND METHODS A retrospective, single-center study was conducted on patients aged 65 years or older with moderate-severe psoriasis who had been undergoing treatment with biologic drugs for at least 60 weeks. RESULTS A total of 168 patients aged 65 years or older with moderate-to-severe psoriasis undergoing biologic therapy were retrieved: 45 were women and with a mean age of 73.23 ± 6.53 years. The decline in mean PASI, BSA, DLQI and NAPSI values over the 60 weeks of treatment was found to be statistically significant at each interval (p < 0.05). Multivariate statistical analysis showed that nearly all the considered independent variables did not influence the response to therapy in terms of PASI score reduction, except for psoriatic arthritis (p = 0.03). DISCUSSION We observed a better response by YOs, with 72.84% of subjects achieving PASI 75 and 71.6% achieving PASI 90 and 100 at the 60th week of treatment. The worst result was obtained by the MOs, with 60 percent of subjects reaching PASI 75 at the end of follow-up, while the OOs had a more mixed performance. The results obtained seem to indicate greater efficacy of anti-TNFα drugs, followed by the other classes of interleukin inhibitors. CONCLUSIONS These results could provide a starting point for new and larger studies and guidelines for biologic treatment.

中文翻译：

---

生物技术药物治疗老年人中重度银屑病的功效和安全性：意大利单中心经验。


背景技术人口变化带来了关于患有中度至重度银屑病的老年患者的生物治疗的许多问题。患者和方法 对 65 岁或以上的中重度银屑病患者进行了一项回顾性单中心研究，这些患者已接受生物药物治疗至少 60 周。结果 共回收 168 例 65 岁以上接受生物治疗的中重度银屑病患者，其中女性 45 例，平均年龄 73.23 ± 6.53 岁。 60 周治疗期间，平均 PASI、BSA、DLQI 和 NAPSI 值的下降在每个时间间隔内均具有统计学显着性 (p < 0.05)。多变量统计分析显示，除了银屑病关节炎外，几乎所有考虑的自变量都不影响 PASI 评分降低对治疗的反应 (p = 0.03)。讨论 我们观察到 YO 的反应更好，在治疗第 60 周时，72.84% 的受试者达到 PASI 75，71.6% 的受试者达到 PASI 90 和 100。 MO 获得的结果最差，60% 的受试者在随访结束时达到 PASI 75，而 OO 的表现则更为复杂。获得的结果似乎表明抗 TNFα 药物的功效更大，其次是其他类别的白细胞介素抑制剂。结论 这些结果可以为新的、更大规模的研究和生物治疗指南提供一个起点。